title: Bacteremia due to Pseudomonas aeruginosa: results from a 3-year national study in the Slovak Republic.
abstract: Risk factors, mortality and antimicrobial susceptibility of Pseudomonas aeruginosa bacteremias isolated from 148 patients from all University Hospitals in Slovakia were analyzed. Only 1.2% of 169 strains of P. aeruginosa were resistant to meropenem, 4.1% to piperacillin/tazobactam, 7.7% to ceftazidime as well as cefepime and 12% to amikacin. More than 30% of P. aeruginosa were resistant to ciprofloxacin. Our analysis of risk factors for antimicrobial resistance to the particular antimicrobials, indicated no difference in risk factors and outcome in cases infected with P. aeruginosa bacteremias resistant to amikacin, piperacillin/tazobactam or ceftazidime in comparison to episodes caused by P. aeruginosa due to susceptible isolates. When comparing risk factors for P. aeruginosa bacteremia in children vs. adults, cancer vs. non-cancer patients, several differences in risk factors were observed. Neither antimicrobial resistance to amikacin, ceftazidime or piperacillin/tazobactam, nor appropriateness of therapy according to two separate analyses were associated with better outcome.
authors.affiliation: Dept of Medicine, University of Trnava, School of Public Health, Slovak Republic.
authors.forename: J
authors.initials: J
authors.lastname: Koprnova
authors.forename: P
authors.initials: P
authors.lastname: Beno
authors.forename: J
authors.initials: J
authors.lastname: Korcova
authors.forename: M
authors.initials: M
authors.lastname: Mrazova
authors.forename: E
authors.initials: E
authors.lastname: Grey
authors.forename: A
authors.initials: A
authors.lastname: Liskova
authors.forename: A
authors.initials: A
authors.lastname: Harnicarova
authors.forename: M
authors.initials: M
authors.lastname: Karvaj
authors.forename: S
authors.initials: S
authors.lastname: Koval
authors.forename: V
authors.initials: V
authors.lastname: Zak
authors.forename: M
authors.initials: M
authors.lastname: Danaj
authors.forename: A
authors.initials: A
authors.lastname: Streharova
authors.forename: E
authors.initials: E
authors.lastname: Mitterpachova
authors.forename: J
authors.initials: J
authors.lastname: Miklosko
authors.forename: A
authors.initials: A
authors.lastname: Ondrusova
authors.forename: J
authors.initials: J
authors.lastname: Riedl
authors.forename: E
authors.initials: E
authors.lastname: Kaiserova
authors.forename: V
authors.initials: V
authors.lastname: Prokopova
authors.forename: M
authors.initials: M
authors.lastname: Hornova
authors.forename: J
authors.initials: J
authors.lastname: Payer
authors.forename: B
authors.initials: B
authors.lastname: Rudinsky
authors.forename: L
authors.initials: L
authors.lastname: Pevalova
authors.forename: M
authors.initials: M
authors.lastname: Bencelova
authors.forename: J
authors.initials: J
authors.lastname: Hanzen
authors.forename: L
authors.initials: L
authors.lastname: Macekova
authors.forename: J
authors.initials: J
authors.lastname: Csölleyova
authors.forename: V
authors.initials: V
authors.lastname: Krcmery
mesh_terms: D000328:Adult; D000367:Age Factors; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016470:Bacteremia; D002648:Child; D024881:Drug Resistance, Bacterial; D005260:Female; D006801:Humans; D008297:Male; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000453:epidemiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification / Q000472:pathogenicity*; D012189:Retrospective Studies; D012307:Risk Factors; D018154:Slovakia / Q000453:epidemiology
chemical_list: D000900:Anti-Bacterial Agents